Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 1,099
- 主要终点
- Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
研究概览
简要总结
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician)
- •Patient is having both eyes treated
排除标准
- •Contraindications per product labelling will apply.
- •Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.
研究组 & 干预措施
1
bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
干预措施: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% (Drug)
结局指标
主要结局
Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year
时间窗: Baseline, 1 Year
Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).
次要结局
未报告次要终点